Literature DB >> 20848552

Factors influencing tumor response to photodynamic therapy sensitized by intratumor administration of methylene blue.

Timothy M Baran1, Benjamin R Giesselman, Rui Hu, Merrill A Biel, Thomas H Foster.   

Abstract

BACKGROUND AND OBJECTIVES: We examined tumor response to methylene blue (MB)-mediated photodynamic therapy (PDT) in a murine tumor model. The goal was to investigate the effects of drug-light interval (DLI), injection vehicle, and fluence on tumor destruction. Fluorescence and reflectance spectroscopy informed our understanding.
MATERIALS AND METHODS: EMT6 tumor cells were implanted intradermally on the backs of female BALB/c mice and grown to ∼4-mm diameter. Mice were given a 35 µl, single site, intratumor injection of 500 µg/ml MB administered in either a water or a 5% ethanol-5% Cremophor-90% saline vehicle. PDT was begun either immediately or after a 1-hour DLI with a fluence rate of 60 mW/cm(2). Each animal received a fluence of 240 or 480 J/cm(2). Fluorescence and reflectance spectra were captured before and during irradiation.
RESULTS: A protocol consisting of the Cremophor-based vehicle, 0 DLI, and a fluence of 480 J/cm(2) was the most effective, with a 55% cure rate as measured by no evidence of tumor 90 days after PDT. Use of the water vehicle with this fluence and DLI reduced the cure rate to 20%. Reducing the fluence to 240 J/cm(2) similarly reduced treatment efficacy with 0 and 1-hour DLIs. Univariate Cox proportional hazards analysis identified increased fluence, 0 versus 1-hour DLI, and the Cremophor versus water vehicle as highly significant independent predictors of long term tumor control (P < 0.01 in each case). Multivariate analysis with model selection revealed fluence and injection vehicle as the best predictors of survival hazards. Fluorescence spectroscopy in vivo showed that MB fluorescence decreased monotonically during a 2-hour dark interval but was restored by irradiation. Reflectance spectroscopy revealed that MB at this injected concentration attenuates the treatment beam significantly.
CONCLUSION: Sensitizer delivery vehicle, drug-light interval, and fluence contribute significantly to the tumor response to MB-mediated PDT.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848552      PMCID: PMC2948599          DOI: 10.1002/lsm.20962

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  21 in total

1.  Intestinal metaplasia of the stomach: identification by a selective mucosal staining technique.

Authors:  M B Fennerty; R E Sampliner; D L McGee; L J Hixson; H S Garewal
Journal:  Gastrointest Endosc       Date:  1992 Nov-Dec       Impact factor: 9.427

2.  Analytical model for extracting intrinsic fluorescence in turbid media.

Authors:  J Wu; M S Feld; R P Rava
Journal:  Appl Opt       Date:  1993-07-01       Impact factor: 1.980

3.  New photodynamic therapy protocol to treat AIDS-related Kaposi's sarcoma.

Authors:  João P Tardivo; Auro Del Giglio; Luis H Paschoal; Mauricio S Baptista
Journal:  Photomed Laser Surg       Date:  2006-08       Impact factor: 2.796

4.  Treatment of melanoma lesions using methylene blue and RL50 light source.

Authors:  J P Tardivo; A Del Giglio; L H C Paschoal; A S Ito; M S Baptista
Journal:  Photodiagnosis Photodyn Ther       Date:  2004-12       Impact factor: 3.631

5.  Methylene blue and the photodynamic therapy of superficial bladder cancer.

Authors:  J L Williams; J Stamp; R Devonshire; G J Fowler
Journal:  J Photochem Photobiol B       Date:  1989-11       Impact factor: 6.252

Review 6.  The present and future role of photodynamic therapy in cancer treatment.

Authors:  Stanley B Brown; Elizabeth A Brown; Ian Walker
Journal:  Lancet Oncol       Date:  2004-08       Impact factor: 41.316

7.  Photochemotherapy of animal tumors with the photosensitizer methylene blue using a krypton laser.

Authors:  K König; V Bockhorn; W Dietel; H Schubert
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

8.  mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients.

Authors:  Anil K D'Cruz; Martin H Robinson; Merrill A Biel
Journal:  Head Neck       Date:  2004-03       Impact factor: 3.147

9.  Photochemotherapy of experimental colonic tumours with intra-tumorally applied methylene blue.

Authors:  K Orth; D Russ; G Beck; A Rück; H G Beger
Journal:  Langenbecks Arch Surg       Date:  1998-08       Impact factor: 3.445

10.  Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer.

Authors:  P-J Lou; H R Jäger; L Jones; T Theodossy; S G Bown; C Hopper
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

View more
  9 in total

1.  Multifunctional Liposomes for Image-Guided Intratumoral Chemo-Phototherapy.

Authors:  Dyego Miranda; Kevin Carter; Dandan Luo; Shuai Shao; Jumin Geng; Changning Li; Upendra Chitgupi; Steven G Turowski; Nasi Li; G Ekin Atilla-Gokcumen; Joseph A Spernyak; Jonathan F Lovell
Journal:  Adv Healthc Mater       Date:  2017-05-15       Impact factor: 9.933

2.  Photoacoustic Imaging Quantifies Drug Release from Nanocarriers via Redox Chemistry of Dye-Labeled Cargo.

Authors:  Ananthakrishnan Soundaram Jeevarathinam; Jeanne E Lemaster; Fang Chen; Eric Zhao; Jesse V Jokerst
Journal:  Angew Chem Int Ed Engl       Date:  2020-01-24       Impact factor: 15.336

Review 3.  Biomodulatory approaches to photodynamic therapy for solid tumors.

Authors:  Sanjay Anand; Bernhard J Ortel; Stephen P Pereira; Tayyaba Hasan; Edward V Maytin
Journal:  Cancer Lett       Date:  2012-07-25       Impact factor: 8.679

4.  Effect of methylene blue-mediated photodynamic therapy for treatment of basal cell carcinoma.

Authors:  Nevien A Samy; Manal M Salah; Maha F Ali; Ahmed M Sadek
Journal:  Lasers Med Sci       Date:  2014-07-17       Impact factor: 3.161

5.  Fluence rate-dependent photobleaching of intratumorally administered Pc 4 does not predict tumor growth delay.

Authors:  Timothy M Baran; Thomas H Foster
Journal:  Photochem Photobiol       Date:  2012-06-06       Impact factor: 3.421

6.  Porphyrin-phospholipid liposomes permeabilized by near-infrared light.

Authors:  Kevin A Carter; Shuai Shao; Matthew I Hoopes; Dandan Luo; Bilal Ahsan; Vladimir M Grigoryants; Wentao Song; Haoyuan Huang; Guojian Zhang; Ravindra K Pandey; Jumin Geng; Blaine A Pfeifer; Charles P Scholes; Joaquin Ortega; Mikko Karttunen; Jonathan F Lovell
Journal:  Nat Commun       Date:  2014-04-03       Impact factor: 14.919

Review 7.  Comparative Study Regarding the Properties of Methylene Blue and Proflavine and Their Optimal Concentrations for In Vitro and In Vivo Applications.

Authors:  Maria-Eliza Nedu; Mihaela Tertis; Cecilia Cristea; Alexandru Valentin Georgescu
Journal:  Diagnostics (Basel)       Date:  2020-04-15

8.  Non-invasive monitoring of alternative splicing outcomes to identify candidate therapies for myotonic dystrophy type 1.

Authors:  Ningyan Hu; Layal Antoury; Timothy M Baran; Soumya Mitra; C Frank Bennett; Frank Rigo; Thomas H Foster; Thurman M Wheeler
Journal:  Nat Commun       Date:  2018-12-07       Impact factor: 14.919

Review 9.  Phthalocyanine and Its Formulations: A Promising Photosensitizer for Cervical Cancer Phototherapy.

Authors:  Lucimara R Carobeli; Lyvia E de F Meirelles; Gabrielle M Z F Damke; Edilson Damke; Maria V F de Souza; Natália L Mari; Kayane H Mashiba; Cristiane S Shinobu-Mesquita; Raquel P Souza; Vânia R S da Silva; Renato S Gonçalves; Wilker Caetano; Márcia E L Consolaro
Journal:  Pharmaceutics       Date:  2021-12-02       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.